FindMyKOL

Frank Cortazar, MD

Basic profile

St Peter's Hospital

ORCIDOn fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionAlbany, NY · NortheastSpecialtyNephrologyFocusNephrology
Active KOLFindMyKOL type: NationalLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Frank Cortazar is a Nephrology physician affiliated with St Peter's Hospital. OpenAlex indexes 74 publications with 3,985 citations (h-index 24).

Overview

Scholarship

indexed output and impact (OpenAlex)
74publications

Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.

3,985citations

Citations across these publications.

24h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
26companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Industry payments

26 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • Amgen
    Program year20253 paymentsResearch
    $291,419
  • Novartis
    Program year20255 paymentsResearch
    $253,648
  • Vertex
    Program year20252 paymentsResearch
    $191,210
All 62 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    49.6%
    Calcium channel blocker10.9%
    Amlodipine Besylate81%Nifedipine Er19%
    Part D<11 patients
    Angiotensin receptor blocker (ARB)10.4%
    Losartan Potassium89%Valsartan11%
    Part D<11 patients

    + 6 more classes in this area

  • Metabolism & gastrointestinal

    34.2%
    Corticosteroid8.9%
    Prednisone100%
    Part D≥28 patients
    SGLT2 inhibitor8.2%
    Farxiga62%Jardiance38%
    Part D≥22 patients

    + 5 more classes in this area

  • Other

    5.9%
    Drugs for treatment of hyperkalemia and hyperphosphatemia5%
    Velphoro50%Auryxia25%Lokelma25%
    Part D<11 patients
    Phosphate Binder0.9%
    Sevelamer Carbonate100%
    Part D<11 patients
Where care is delivered (Part B)58.7% facility · 41.3% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”